UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4295) 4295
rituximab (3925) 3925
science & technology (3603) 3603
life sciences & biomedicine (3571) 3571
female (2480) 2480
male (2439) 2439
middle aged (2078) 2078
antibodies, monoclonal, murine-derived (1986) 1986
adult (1725) 1725
aged (1637) 1637
treatment outcome (1426) 1426
antibodies, monoclonal - therapeutic use (1334) 1334
antibodies, monoclonal, murine-derived - therapeutic use (1300) 1300
hematology (1229) 1229
biological and medical sciences (1185) 1185
medical sciences (1182) 1182
oncology (1141) 1141
antibodies, monoclonal, murine-derived - adverse effects (1046) 1046
antineoplastic combined chemotherapy protocols - therapeutic use (972) 972
antibodies, monoclonal - adverse effects (970) 970
antibodies, monoclonal, murine-derived - administration & dosage (917) 917
antibodies, monoclonal - administration & dosage (706) 706
aged, 80 and over (659) 659
antineoplastic combined chemotherapy protocols - adverse effects (632) 632
antineoplastic agents - therapeutic use (593) 593
hematologic and hematopoietic diseases (573) 573
cyclophosphamide - administration & dosage (571) 571
immunologic factors - therapeutic use (571) 571
care and treatment (552) 552
antineoplastic agents - adverse effects (534) 534
retrospective studies (520) 520
antineoplastic agents (469) 469
immunosuppressive agents - therapeutic use (469) 469
adolescent (468) 468
lymphoma, large b-cell, diffuse - drug therapy (468) 468
abridged index medicus (467) 467
chemotherapy (462) 462
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (456) 456
cancer (450) 450
antineoplastic combined chemotherapy protocols - administration & dosage (449) 449
young adult (438) 438
rheumatology (436) 436
medicine & public health (433) 433
vincristine - administration & dosage (430) 430
transplantation (425) 425
recurrence (420) 420
lymphomas (417) 417
doxorubicin - administration & dosage (409) 409
disease-free survival (404) 404
remission induction (393) 393
drug therapy (392) 392
cyclophosphamide - adverse effects (387) 387
pharmacology. drug treatments (387) 387
prednisone - administration & dosage (385) 385
lymphoma (376) 376
prognosis (376) 376
immunology (374) 374
cyclophosphamide - therapeutic use (366) 366
follow-up studies (366) 366
risk factors (351) 351
drug administration schedule (338) 338
immunotherapy (326) 326
drug therapy, combination (325) 325
lymphoma, non-hodgkin - drug therapy (308) 308
child (299) 299
prednisone - therapeutic use (298) 298
antineoplastic agents - administration & dosage (294) 294
antimitotic agents (291) 291
lymphoma, b-cell - drug therapy (289) 289
vincristine - adverse effects (287) 287
immunologic factors - adverse effects (286) 286
doxorubicin - adverse effects (281) 281
time factors (281) 281
b-lymphocytes - immunology (280) 280
research (274) 274
arthritis, rheumatoid - drug therapy (273) 273
antirheumatic agents - therapeutic use (271) 271
health aspects (268) 268
prednisone - adverse effects (267) 267
antigens, cd20 - immunology (263) 263
animals (262) 262
immunosuppressive agents - adverse effects (256) 256
combined modality therapy (253) 253
monoclonal antibodies (253) 253
lymphoma, follicular - drug therapy (252) 252
leukemia, lymphocytic, chronic, b-cell - drug therapy (250) 250
tumors (249) 249
b-lymphocytes - drug effects (244) 244
vincristine - therapeutic use (236) 236
antirheumatic agents - adverse effects (235) 235
cyclophosphamide (231) 231
doxorubicin - therapeutic use (227) 227
prospective studies (220) 220
general & internal medicine (219) 219
rheumatoid arthritis (219) 219
analysis (217) 217
medicine, general & internal (210) 210
survival analysis (210) 210
hemic and lymphatic diseases (200) 200
immunologic factors - administration & dosage (199) 199
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4196) 4196
Japanese (49) 49
German (39) 39
Spanish (37) 37
French (34) 34
Chinese (29) 29
Italian (14) 14
Russian (10) 10
Polish (6) 6
Portuguese (6) 6
Croatian (5) 5
Danish (5) 5
Czech (4) 4
Hungarian (4) 4
Dutch (3) 3
Finnish (2) 2
Hebrew (2) 2
Norwegian (2) 2
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 25, pp. 5996 - 6004
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 5, pp. 417 - 427
WEGENERS-GRANULOMATOSIS | MAINTENANCE | ANTIBODY-ASSOCIATED VASCULITIS | RENAL VASCULITIS | CYCLOPHOSPHAMIDE | RITUXIMAB | ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES | RANDOMIZED-TRIAL | SYSTEMIC VASCULITIDES | CELL-ACTIVATION | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis | Recurrence | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Double-Blind Method | Drug Administration Schedule | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | B-Lymphocytes | Rituximab | Cyclophosphamide - adverse effects | Remission Induction | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Cyclophosphamide - therapeutic use | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Drug Therapy, Combination | Antibodies, Monoclonal, Murine-Derived - adverse effects | Azathioprine - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use | Immunosuppression | Vasculitis | Drug therapy | Patient outcomes | Disease | Medical treatment | Hypersensitivity | Patients | Immunosuppressive agents | Cyclophosphamide | Infectious diseases | Lymphocytes B | Antineutrophil cytoplasmic antibodies | Remission | Azathioprine | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 196 - 206
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Index Medicus | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology | Lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality
Journal Article
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 2, pp. 174 - 181
Journal Article
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 19, pp. 2944 - 2952
Journal Article